Piramal Acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.

-
The Telegraph reports that Piramal announced that it has invested USD 30.65 million towards acquiring Coldstream Laboratories Inc. (‘Coldstream’), through its wholly owned subsidiary in the USA in an all cash transaction.
 
Coldstream is a Contract Development and Manufacturing Organisation (CDMO) focused on the development and manufacturing of sterile injectable products. Coldstream was founded in 2007 and is majority owned by University of Kentucky Research Foundation (an affiliate of the University of Kentucky). Coldstream is a specialty pharmaceutical contract manufacturer with an emphasis on clinical trial to commercial-scale manufacturing of sterile liquid and lyophilized parenterals and injectables. Coldstream has developed differentiated expertise to formulate and manufacture high potency and cytotoxic compounds including Antibody Drug Conjugates (ADCs). The company operates from a FDA approved facility located in Lexington, Kentucky, USA.
  
Commenting on the acquisition Mr. Vivek Sharma, CEO of PEL’s Pharma Solutions business said “Coldstream is a very high quality operation and has been able to build significant customer relationships and track record for sterile products. We see this as a great platform for growth in our Pharma Solutions business. This acquisition allows PEL to move further into the injectable market segment and should have strong synergy with our existing Pharma Solutions business. Our strong capabilities in sterile product development and in ADC product segment will allow us to offer an integrated solution to our customers.” Bill Wedlake, President of PEL’s Pharma Solutions Formulations business added, “We have been impressed by the quality of the people at Coldstream and their success in both attracting high quality business and also their track record in quality. Coldstream’s use of isolator technology is impressive and provides a foundation for expansion of the facility to provide large scale commercial manufacturing including production of highly potent compounds.”
 

Comments

Post a Comment

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

-
The China-India joint summit held recently discussed bilateral trade to improve Indo- China pharma industry and address issues like long product registration time and high fees for product registration in China’s drug regulatory system, among other issues.  Besides this, other relevant key issues related to transparency in public procurement system in China and clinical trial related approvals were also deliberated at the summit organised under the aegis of Indian Pharmaceutical Association (IPA), Shengjie and SaSPinjara, China between May 16 and May 17, 2019 at Pullman Shanghai South, China. The summit was focused on enhancing export business for both the nations across the globe. Senior health ministry official from Government of Gujarat Punamchand Parmar was invited as the Chief Guest of the summit and Gujarat Food and Drugs Control Administration (FDCA) Commissioner Dr Hemant Koshia was invited as Guest of Honour.  Among other dignitaries, Dr. Anil Kumar Rai, Consulate General of
Read more

Webinar on ‘OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH’

-
Image
“IDEA TO MARKET” is an idea hunt to commercialize the herbal inventions. It is a platform for researchers to use their innovative ideas in the area of herbal research and get the products commercialized in collaboration with corporate partners.  Hurry up and register for the webinar to know more about this program. The webinar is organized by Bombay College of Pharmacy and Pharma Literati.  Registration Link for webinar on OPPORTUNITY TO COMMERCIALIZE HERBAL RESEARCH: https://docs.google.com/forms/d/e/1FAIpQLSfUhe1LtCOjG50SilFw_iECnzBXu4CW0nK2wIvd8QVVvpDOzQ/viewform
Read more